Social Media Ideas for Bkbdx

Beigene

Beigene Anonymous (not verified) Mon, 05/25/2026 - 11:38 field_thread_url https://cafepharma.com/boards/threads/beigene.637588/ board na...

Dividend Kings In Focus: Becton, Dickinson & Company

Updated on July 9th, 2026 by Nathan Parsh Becton, Dickinson & Company (BDX) has increased its dividend for 54 consecutive years, and as a result, it recently joined the exclusi...

BridgeBio: "Strong Buy" Attruby Differentiation And Several NDA Submissions In Play

KeyBanc reiterates Omnicell stock rating on Titan XT launch

Kiniksa

Kiniksa Anonymous (not verified) Tue, 05/19/2026 - 08:34 field_thread_url https://cafepharma.com/boards/threads/kiniksa.658756/ board na...

ImmunityBio: Could Be One Approval Away From A Multi-Billion Dollar Breakout

<![CDATA[Pharmaceutical Executive Daily: Kardigan Sets Terms for $350 Million IPO]]>

Form 4 Kyntra Bio Inc For: 17 June

Kiniksa

Kiniksa Anonymous (not verified) Fri, 06/05/2026 - 17:45 field_thread_url https://cafepharma.com/boards/threads/kiniksa.658756/ board na...

BlackRock Global Dividend Fund Q1 2026 Commentary

Bicara Therapeutics Inc. (BCAX) Discusses New Clinical Data on Investigational Therapy for HPV Negative Head and Neck Ca...

BingX Launches SK Hynix ADR Pre-IPO Trading with a $100,000 Prediction Campaign

BingX, a leading cryptocurrency exchange and Web3-AI company, today announced the launch of SK Hynix ADR pre-IPO trading on its platform, ahead of the semiconductor giant’s highly...

What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors?

This Boston-based biotech, focused on bifunctional antibody therapies for cancer, just reported a notable insider sale in recent filings.

Sangamo holds a bankruptcy sale; VCs back a China-linked Beam competitor

Eli Lilly and Astellas will be the lead bidders at an auction for Sangamo assets. Elsewhere, an investor syndicate committed $230 million to a gene editing startup and Merck KGaA s...

BridgeBio

BridgeBio Anonymous (not verified) Thu, 07/09/2026 - 09:10 field_thread_url https://cafepharma.com/boards/threads/bridgebio.698762/ boar...

PDSB Q4 2025 Earnings Call Transcript

Image source: The Motley Fool. DATEWednesday, May 13, 2026 at 8 a.m. ETCALL PARTICIPANTSChief Executive Officer — Frank Bedu-AddoChief Medical Officer — Kirk ShepardChief Financia...

Nurix Therapeutics, Inc. (NRIX) Discusses Strategic Collaboration for Development and Commercialization of Bexobrutideg...

Why One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally

This clinical-stage biotech develops innovative retinal disease therapies, with its lead candidate advancing through late-stage trials.

BK Technologies: An Attractive Margin Of Safety With Multi-Bagger Potential

BNDW: Has Unnecessary Exposures

Alkermes: 'Buy' On Avadel Acquisition And Positive NT2 Data With Alixorexton

BioMarin Pharmaceutical

BioMarin Pharmaceutical Anonymous (not verified) Mon, 06/22/2026 - 00:00 field_thread_url https://cafepharma.com/boards/threads/biomarin-pharmaceutical.710...

Eledon Pharmaceuticals, Inc. (ELDN) Discusses Updated Long-term Data From Phase 2 BESTOW Clinical Trial in Kidney Transp...

Ipsen’s $450M blood cancer drug; FDA selects first cohort for “pre-check” pilot program

The planned acquisition of Kartos Therapeutics would hand Ipsen a late-stage asset for myelofibrosis. Elsewhere, Sobi hit a regulatory setback and BeOne unveiled more positive Bruk...